Prevalence of resistance-associated mutations in Human Immunodeficiency Virus type 1-positive individuals failing HAART in Rio de Janeiro, Brazil

Brazilian Journal of Infectious Diseases

Volumn 12, Issue 5, 2008, Pages 380-384

  Varella, Rafael Brandão ^a   Ferreira, Selma Baía ^a   de Castro, Márcia Braga ^a   Tavares, Marisa Dias ^a   Zalis, Mariano Gustavo ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

HAART; HIV 1; Protease; Resistance; Reverse transcritase

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ASPARAGINE; ASPARTIC ACID; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LEUCINE; LYSINE; METHIONINE; NELFINAVIR; NEVIRAPINE; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; TENOFOVIR; THREONINE; TIPRANAVIR; TRYPTOPHAN; TYROSINE; VALINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BRAZIL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREVALENCE; RNA EXTRACTION; SEQUENCE ANALYSIS; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; MUTATION; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 65449140352     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702008000500007     Document Type: Article

References (40)

1. Gallant J.E. Initial therapy of HIV infection. J Clin Virol 2002; 25:317-33.
2. Werner V., Stephen B., Calvin C., et al. Prevalence of HIV drug resistance in anti-retroviral-naive patients: a prospective study. AIDS 2001;15(5):647-50.
3. Perno C.F., Cozzi-Lepri A., Balotta C., et al. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naïve patients treated with protease inhibitor-based therapy. J Infect Dis 2001;184:983-91.
4. Marins J.R., Jamal L.F., Chen S.Y., et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 2003; 17(11):1675-1682.
5. Perez E.E., Rose S.L., Peyser S.L.L., Burkhart B. Human Immunodeficiency Virus Type 1 Protease Genotype Predicts Immune and Viral Responses to Combination Therapy with Protease Inhibitors (PIs) in PI-Naïve Patients. J Infect Dis 2001;183:579-88.
6. Soares M.A., Brindeiro R.M., Tanuri A. Primary HIV-1 drug resistance in Brazil. AIDS 2004;18 (suppl 3): S9-S13.
7. Ho D.D., Neumann A.U., Perelson A.S., et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-6.
8. Brenner B., Wainberg M.A., Salomon H., Danielle R. Resistance to anti-retroviral drugs in patients with primary HIV-1 infection. Int J Anti Agents 2000;16(4):429-34.
9. Eigen M. Viral quasispecies. Sci Am 1993;269:42-9.
10. Shafer R.W., Vuitton D.A. Highly active anti-retroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed and Pharmacother 1999; 25:73-86.
11. Wu T.D., Schiffer C.A., Gonzales M.J., et al. Mutation Patterns and Structural Correlates in Human Immunodeficnecy Virus Type 1 Protease following Different Protease Inhibitor Treatments. J Virology 2003;77(8): 4836-47.
12. Ceccherini F. Identification of the minimal conserved structured of HIV-1 protease in the presence and absence of drug pressure. AIDS 2004;18:11-9.
13. Cao Y., Qin L., Zhang L., et al. Virologic and immunologic characterization of longterm survivors of human immunodeficiency virus type 1 infection. N Eng J Med 1995;332:201-8.
14. Mellors J.W., Rinaldo C.R., Gupta P., et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-70.
15. Hammer S.M., Türman T., Vareldziz B., et al. Antiretroviral guidelines for resource-limited settings: the WHO's public health approach. Nature Med 2002;8:649-50.
16. Ministério da Saúde. Coordenação Nacional de DST e AIDS. Projeto de Implantação de uma Rede Nacional para Genotipagem do HIV-1 (RENAGENO) em Pacientes com Falha Terapêutica aos Anti-retrovirais, 2001.
17. Baxter J.D., Mayers D.L., Wentworth D.N. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000; 14:F83-F93.
18. Durant J. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. The Lancet 1999;353: 2195-9.
19. Meynard J.L. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002;16:727-36.
20. Johnson V.A., Brun-Vézinet F., Clolet B., et al. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med 2006; 14(3):125-30.
21. Lee N., Hogg R.S., Yip B., et al. Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy. J infect Dis 2003;188:137-41.
22. Little S.J., Holte S., Routy J.P., et al. Antiretroviral drugs resistance among patients recently infected with HIV. New Engl J Med 2002; 347: 385-94.
23. Malta M., Petersen M.L., Clair S., et al. Adherence to antiretroviral therapy: a qualitative study with physicians from Rio de Janeiro, Brazil. Cad Saúde Pública 2005;21(5):1424-32.
24. Shaffer R. Genotypic testing for human immunodeficiency virus type 1 drug resistance Clinical Microbiology Reviews 2002;15:247-77.
25. D'Aquila R.T. Incorporating Anti-retroviral Resistance Testing Into Clinical Practice. Medical Education Collaborative 2002.
26. Chequer P. Apresentação do boletim de Aids. In: Coordenação Nacional de DST e Aids (ed.). Boletim Epidemiológico de Aids 2004. Brasília: Ministério da Saúde; 2004.
27. Brito A.M., Castilho E.A., Szwarcwald C.L. Aids e infecção pelo HIV no Brasil: uma epidemia multifacetada. Rev Soc Bras Med Trop 2000;34:207-17.
28. Szwarcwald C.L., Bastos F.I., Andrade C.L.T., et al. Aids: o mapa ecológico do Brasil, 1982-1994. In: Coordenação Nacional de DST e Aids (ed.). A epidemia da Aids no Brasil: situação e tendências. Brasília: Ministério da Saúde; 1997. p. 27-44.
29. Morgado M.G., Guimaraes M.L., Gripp C.B., et al. Molecular epidemiology of HIV-1 in Brazil: high prevalence of HIV-1 subtype B and identification of an HIV-1 subtype D infection in the city of Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 1998; 18(5):488-94.
30. Tupinambás U., Ribeiro F.A., Aleixo A., Greco D. Treatment switch guided by HIV-1 genotyping in Brazil. Braz J Infect Dis 2006; 10(2):82-8.
31. Da Costa S.M., Schechter M., Shindo N., et al. Sequence and phylogenetic analysis of glycoprotein 120 of an HIV type 1 variant (GWGR) prevalent in Brazil. AIDS Res Hum Retroviruses 1998;11(9):1143-5.
32. Sabino E.C., Diaz R.S., Brigido L.F., et al. Distribution of HIV-1 subtypes seen in an AIDS clinic in Sao Paulo City, Brazil. AIDS 1996;10(13):1579- 84.
33. Brindeiro R.M., Diaz R.S., Sabino E.C., et al. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS 2003;17:1063-9.
34. Couto-Fernandez J.C., Silva-de-Jesus C., Rachid M., et al. Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drugresistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy. Mem Inst Oswaldo Cruz 2005; 100(1): 73-8.
35. Tanuri A., Caridea E., Dantas M.C., et al. Prevalence of mutations related to HIV-1 antiretroviral resistance in Brazilian patients failing HAART. J Clin Virol 2002;(25) 39-45.
36. Castilho L.T., Herrera-Martínez G., León-Bratti M., et al. Study of antiretroviral mutants in HIV patients with treatment failures and the effect of risk factors in the virological failures. Rev Inst Med trop S Paulo 2005; 47(6): 327-31.
37. Kristiansen T.B., Pedersen A.G., Eugen-Olsen J., et al. Genetic evolution of HIV in patients on stable HAART regimen despite insufficient viral suppression. Scandinavian J Infect Dis 2005;37: 890-1.
38. Harrigan P.R., Hogg R.S., Dong W.W.Y., et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naïve cohort initiating triple antiretroviral therapy. J Infect Dis 2004; 191:339-47.
39. Leal E.S., Holmes E.C., Zanotto P.M. Distinct patterns of natural selection in the reverse transcriptase gene of HIV-1 in the presence and absence of antiretroviral therapy. Virology 2004;325:181-91.
40. Louie M., Markowitz M. Goals and milestones during treatment of HIV-1 infection with anti-retroviral therapy: a pathogenesis-based perspective. Antiviral Research 2002;55:5-15.